Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Alesta Therapeutics

Ownership
Private
Therapeutic Areas
Rare DiseasesNeurology
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small moleculesoral small molecules

Alesta Therapeutics General Information

Lead program ALE1 is progressing through GLP toxicology studies with plans to initiate clinical studies in 2025. ALE2 is in development for CMT disease.

Contact Information

Website
https://alestatherapeutics.com/
Primary Industry
Biotech
Corporate Office
Leiden,
Netherlands

Drug Pipeline

ALE1
Pre-clinical
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Alesta Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Alesta Therapeutics Funding

Deal TypeDateAmountStatusStage
InvestmentJan 8, 2025$70.8MCompletedPreclinical
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Alesta Therapeutics's complete valuation and funding history, request access »

Alesta Therapeutics Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals